Osteoprotegerin, Human, ELISA Kit

データシート

• 商品コード：RD194003200
• メーカー：BLM
• 包装：1kit
• 価格： ¥125,000
• 在庫：無(未発注)

マイリストに追加 マイリストに追加済

• No.： 1
• 文献情報：
  Stejskal D et al. Osteoprotegerin, RANK, RANKL. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2001 Dec;145(2):61-4
  Stejskal D et al
  2001/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 2
• 文献情報：
  Stejskal D et al. Osteoprotegerin and bone density. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2001 Dec;145(2):75-6
  Stejskal D et al
  2001/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 3
• 文献情報：
  Naylor KE et al. Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J. Clin. Endocrinol. Metab. 2003 Nov;88(11):5361-5
  Naylor KE et al
  2003/01/01
  
• 備考：
  
• 参照：
  

• No.： 4
• 文献情報：
  Kyrtsonis MC et al. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Eur. J. Haematol. 2004 Apr;72(4):252-8
  Kyrtsonis MC et al
  2004/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 5
• 文献情報：
  Dai SM et al. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. Ann. Rheum. Dis. 2004 Nov;63(11):1379-86
  Dai SM et al
  2004/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 6
• 文献情報：
  Avbersek-Luznik I et al. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrol. Dial. Transplant. 2005 Mar;20(3):566-70
  Avbersek-Luznik I et al
  2005/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 7
• 文献情報：
  Skl叩dal P et al. Investigation of osteoprotegerin interactions with ligands and antibodies using piezoelectric biosensors. Biosens Bioelectron 2005 Apr;20(10):2027-34
  Skl叩dal P et al
  2005/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 8
• 文献情報：
  Ma誰moun L et al. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury. Calcif. Tissue Int. 2005 Jun;76(6):404-11
  Ma誰moun L et al
  2005/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 9
• 文献情報：
  Rogers A et al. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J. Clin. Endocrinol. Metab. 2005 Nov;90(11):6323-31
  Rogers A et al
  2005/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 10
• 文献情報：
  Avignon A et al. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 2005 Sep;28(9):2176-80
  Avignon A et al
  2005/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 11
• 文献情報：
  Kim SM et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin. Endocrinol. (Oxf) 2005 Nov;63(5):594-8
  Kim SM et al
  2005/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 12
• 文献情報：
  Morena M et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J. Am. Soc. Nephrol. 2006 Jan;17(1):262-70
  Morena M et al
  2006/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 13
• 文献情報：
  Garc鱈a-Valdecasas-Campelo E et al. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. Alcohol Alcohol. ;41(3):261-6
  Garc鱈a-Valdecasas-Campelo E et al
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 14
• 文献情報：
  Kanzaki H et al. Cyclical tensile force on periodontal ligament cells inhibits osteoclastogenesis through OPG induction. J. Dent. Res. 2006 May;85(5):457-62
  Kanzaki H et al
  2006/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 15
• 文献情報：
  Morena M et al. The role of mineral metabolism and inflammation on dialysis vascular access failure. J Vasc Access ;7(2):77-82
  Morena M et al
  
• 備考：
  
• 参照：
  

• No.： 16
• 文献情報：
  Bargnoux AS et al. Renal transplantation decreases osteoprotegerin levels. Transplant. Proc. 2006 Sep;38(7):2317-8
  Bargnoux AS et al
  2006/01/01
  
• 備考：
  
• 参照：
  

• No.： 17
• 文献情報：
  Ulivieri FM et al. Increased osteoprotegerin in Italian haemodialysis patients. Osteoporos Int 2006 Dec;17(12):1822-3; author reply 1824
  Ulivieri FM et al
  2006/01/01
  
• 備考：
  
• 参照：
  

• No.： 18
• 文献情報：
  Clancy P et al. Assessment of a serum assay for quantification of abdominal aortic calcification. Arterioscler. Thromb. Vasc. Biol. 2006 Nov;26(11):2574-6
  Clancy P et al
  2006/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 19
• 文献情報：
  Gogo PB et al. Osteoprotegerin is not associated with angiographic coronary calcification. J. Thromb. Thrombolysis 2006 Dec;22(3):177-83
  Gogo PB et al
  2006/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 20
• 文献情報：
  Guldiken B et al. Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thromb. Res. 2007;120(4):511-6
  Guldiken B et al
  2007/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 21
• 文献情報：
  Ozkaya O et al. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis. Nephron Clin Pract 2007;105(4):c153-8
  Ozkaya O et al
  2007/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 22
• 文献情報：
  Mora S et al. Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. AIDS 2007 May;21(9):1129-35
  Mora S et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 23
• 文献情報：
  Golledge J et al. Relationship between CT anthropometric measurements, adipokines and abdominal aortic calcification. Atherosclerosis 2008 Mar;197(1):428-34
  Golledge J et al
  2008/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 24
• 文献情報：
  Avignon A et al. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care 2007 Nov;30(11):2934-9
  Avignon A et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 25
• 文献情報：
  Shaarawy M et al. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure. Clin. Chem. Lab. Med. 2007;45(11):1498-503
  Shaarawy M et al
  2007/01/01
  
• 備考：
  
• 参照：
  

• No.： 26
• 文献情報：
  Sultan A et al. Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemia in type 2 diabetic patients. Diabetes Care 2008 Mar;31(3):593-5
  Sultan A et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 27
• 文献情報：
  Nybo M et al. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur. J. Endocrinol. 2008 Nov;159(5):603-8
  Nybo M et al
  2008/01/01
  
• 備考：
  
• 参照：
  

• No.： 28
• 文献情報：
  Shargorodsky M et al. Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women. Atherosclerosis 2009 Jun;204(2):608-11
  Shargorodsky M et al
  2009/01/01
  
• 備考：
  Species: Human, Applications: Serum,Plasma-EDTA,Plasma-Heparin,Plasma-Citrate,Cell culture medium,Synovial fluid
• 参照：
  

• No.： 29
• 文献情報：
  Mencej-Bedrac S et al. The combinations of polymorphisms in vitamin D receptor, osteoprotegerin and tumour necrosis factor superfamily member 11 genes are associated with bone mineral density. J. Mol. Endocrinol. 2009 Mar;42(3):239-47
  Mencej-Bedrac S et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 30
• 文献情報：
  Dundar U et al. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study. J. Bone Miner. Metab. 2009;27(4):464-70
  Dundar U et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 31
• 文献情報：
  Tibullo D et al. Effects of imatinib mesylate in osteoblastogenesis. Exp. Hematol. 2009 Apr;37(4):461-8
  Tibullo D et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 32
• 文献情報：
  Doumouchtsis K et al. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease. Ther Apher Dial 2009 Feb;13(1):49-55
  Doumouchtsis K et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 33
• 文献情報：
  Marchelli D et al. Increased serum OPG in atrophic nonunion shaft fractures. J Orthop Traumatol 2009 Jun;10(2):55-8
  Marchelli D et al
  2009/01/01
  
• 備考：
  
• 参照：
  

• No.： 34
• 文献情報：
  Vanella L et al. HO-1 expression increases mesenchymal stem cell-derived osteoblasts but decreases adipocyte lineage. Bone 2010 Jan;46(1):236-43
  Vanella L et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 35
• 文献情報：
  Barbagallo I et al. Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation. J. Bone Miner. Metab. 2010 May;28(3):276-88
  Barbagallo I et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 36
• 文献情報：
  Kolahi S et al. Fish oil supplementation decreases serum soluble receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in female patients with rheumatoid arthritis. Clin. Biochem. 2010 Apr;43(6):576-80
  Kolahi S et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 37
• 文献情報：
  Shaker OG et al. Possible role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as markers of plaque instability in coronary artery disease. Angiology 2010 Nov;61(8):756-62
  Shaker OG et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 38
• 文献情報：
  Ochiai M et al. Vitamin K? alters bone metabolism markers in hemodialysis patients with a low serum parathyroid hormone level. Nephron Clin Pract 2011;117(1):c15-9
  Ochiai M et al
  2011/01/01
  
• 備考：
  
• 参照：
  

• No.： 39
• 文献情報：
  Chen CH et al. Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin. Rheumatol. 2010 Oct;29(10):1155-61
  Chen CH et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 40
• 文献情報：
  Gonz叩lez-Reimers E et al. Prognosis of osteopenia in chronic alcoholics. Alcohol 2011 May;45(3):227-38
  Gonz叩lez-Reimers E et al
  2011/01/01
  
• 備考：
  
• 参照：
  

• No.： 41
• 文献情報：
  Cao JJ et al. A diet high in meat protein and potential renal acid load increases fractional calcium absorption and urinary calcium excretion without affecting markers of bone resorption or formation in postmenopausal women. J. Nutr. 2011 Mar;141(3):391-7
  Cao JJ et al
  2011/01/01
  
• 備考：
  
• 参照：
  

• No.： 42
• 文献情報：
  Dimitrow PP et al. The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. J. Heart Valve Dis. 2011 Jan;20(1):18-22
  Dimitrow PP et al
  2011/01/01
  
• 備考：
  
• 参照：
  

• No.： 43
• 文献情報：
  Takeda Y. [Evaluation of bone mineral turnover in children with nephrotic syndrome--the implications of original disease and the effects of corticosteroids on bone metabolism]. Nihon Jinzo Gakkai Shi 1993 Jun;35(6):705-13
  Takeda Y
  1993/01/01
  
• 備考：
  
• 参照：
  

• No.： 44
• 文献情報：
  Abd El Dayem SM et al. Bone mineral density, bone turnover markers, lean mass, and fat mass in Egyptian children with congenital adrenal hyperplasia. Arch Med Sci 2010 Mar;6(1):104-10
  Abd El Dayem SM et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 45
• 文献情報：
  Albu A et al. Bone metabolism regulators and arterial stiffness in postmenopausal women. Maturitas 2013 Oct;76(2):146-50
  Albu A et al
  2013/01/01
  
• 備考：
  
• 参照：
  

• No.： 46
• 文献情報：
  Boyapati A et al. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY. Arthritis Res. Ther. 2016
  Boyapati A et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 47
• 文献情報：
  Cao H et al. Serum sRANKL/OPG predict recurrence after radiofrequency catheter ablation of lone atrial fibrillation. Int. J. Cardiol. 2014 Jan;170(3):298-302
  Cao H et al
  2014/01/01
  
• 備考：
  
• 参照：
  

• No.： 48
• 文献情報：
  Cao H et al. Preoperative serum soluble receptor activator of nuclear factor-κB ligand and osteoprotegerin predict postoperative atrial fibrillation in patients undergoing cardiac valve surgery. Ann. Thorac. Surg. 2013 Sep;96(3):800-6
  Cao H et al
  2013/01/01
  
• 備考：
  
• 参照：
  

• No.： 49
• 文献情報：
  Chae SY et al. The Correlation of Serum Osteoprotegerin with Non-Traditional Cardiovascular Risk Factors and Arterial Stiffness in Patients with Pre-Dialysis Chronic Kidney Disease: Results from the KNOW-CKD Study. J. Korean Med. Sci. 2018 Dec;33(53):e322
  Chae SY et al
  2018/01/01
  
• 備考：
  
• 参照：
  

• No.： 50
• 文献情報：
  di Giuseppe R et al. Plasma osteoprotegerin, its correlates, and risk of heart failure: a prospective cohort study. Eur. J. Epidemiol. 2017 02;32(2):113-123
  di Giuseppe R et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 51
• 文献情報：
  El-Shehaby A et al. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J. Clin. Immunol. 2011 Oct;31(5):848-56
  El-Shehaby A et al
  2011/01/01
  
• 備考：
  
• 参照：
  

• No.： 52
• 文献情報：
  Ford ML et al. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. Nephrol. Dial. Transplant. 2012 Feb;27
  Ford ML et al
  2012/01/01
  
• 備考：
  
• 参照：
  

• No.： 53
• 文献情報：
  Friedmann A et al. Receptor activator of NF-kappaB ligand (RANKL) and CD 31 expressions in chronic periodontitis patients before and after surgery. Cent Eur J Immunol 2014;39(4):508-17
  Friedmann A et al
  2014/01/01
  
• 備考：
  
• 参照：
  

• No.： 54
• 文献情報：
  Gossiel F et al. The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study. Bone 2016 11;92:94-99
  Gossiel F et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 55
• 文献情報：
  Kim CS et al. Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study. PLoS ONE 2016;11(11):e0166792
  Kim CS et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 56
• 文献情報：
  Kolonko A et al. Cardiovascular Risk Factors and Markers of Atherosclerosis in Stable Kidney Transplant Recipients. Transplant. Proc. 2016 Jun;48(5):1543-50
  Kolonko A et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 57
• 文献情報：
  Krela-Ka添mierczak I et al. Bone Metabolism and the c.-223C > T Polymorphism in the 5'UTR Region of the Osteoprotegerin Gene in Patients with Inflammatory Bowel Disease. Calcif. Tissue Int. 2016 12;99(6):616-624
  Krela-Ka添mierczak I et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 58
• 文献情報：
  Motovska Z et al. Circulating osteoprotegerin and Dickkopf-1 changed significantly after surgical aortic valve replacement but remained without any significant differences after transcatheter aortic valve implantation. Int. J. Cardiol. 2012 Jul;158(2):300
  Motovska Z et al
  2012/01/01
  
• 備考：
  
• 参照：
  

• No.： 59
• 文献情報：
  Najar M et al. Breast cancer cells and bone marrow mesenchymal stromal cells: a regulated modulation of the breast tumor in the context of immune response. Inflamm. Res. 2017 Feb;66(2):129-139
  Najar M et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 60
• 文献情報：
  Nakahara T et al. Fibroblast growth factor 23 inhibits osteoblastic gene expression and induces osteoprotegerin in vascular smooth muscle cells. Atherosclerosis 2016 10;253:102-110
  Nakahara T et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 61
• 文献情報：
  Öztürk VÖ et al. Impact of implant-abutment connection on osteoimmunological and microbiological parameters in short implants: a randomized controlled clinical trial. Clin Oral Implants Res 2017 Sep;28(9):e111-e120
  Öztürk VÖ et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 62
• 文献情報：
  Passeri E et al. Effects of 12-months treatment with zoledronate or teriparatide on intima-media thickness of carotid artery in women with postmenopausal osteoporosis: A pilot study. Int J Immunopathol Pharmacol 2019;33:2058738418822439
  Passeri E et al
  2019/01/01
  
• 備考：
  
• 参照：
  

• No.： 63
• 文献情報：
  Salah H et al. The clinical significance of OPG/sRANKL ratio in thalassemia patients suffering from osteopenia or osteoporosis in Egyptian patients. Immunol Invest 2010;39(8):820-32
  Salah H et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 64
• 文献情報：
  Salama HM et al. The effects of L-thyroxin replacement therapy on bone minerals and body composition in hypothyroid children. Arch Med Sci 2010 Jun;6(3):407-13
  Salama HM et al
  2010/01/01
  
• 備考：
  
• 参照：
  

• No.： 65
• 文献情報：
  Silva HC et al. Higher prevalence of morphometric vertebral fractures in patients with recent coronary events independently of BMD measurements. Bone 2013 Feb;52(2):562-7
  Silva HC et al
  2013/01/01
  
• 備考：
  
• 参照：
  

• No.： 66
• 文献情報：
  Stavroulopoulos A et al. Evolution of coronary artery calcification in patients with chronic kidney disease Stages 3 and 4, with and without diabetes. Nephrol. Dial. Transplant. 2011 Aug;26(8):2582-9
  Stavroulopoulos A et al
  2011/01/01
  
• 備考：
  
• 参照：
  

• No.： 67
• 文献情報：
  Tousoulis D et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol 2013 Sep;167(5):1924-8
  Tousoulis D et al
  2013/01/01
  
• 備考：
  
• 参照：
  

• No.： 68
• 文献情報：
  テ奔den FO et al. Effect of bisphosphonate as an adjunct treatment for chronic periodontitis on gingival crevicuar fluid levels of nuclear factor-κB ligand (RANKL) and osteoprotegerin in postmenopausal osteoporosis. J Oral Sci 2017;59(1):147-155
  テ奔den FO et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 69
• 文献情報：
  Vezzani G et al. Hyperbaric oxygen therapy modulates serum OPG/RANKL in femoral head necrosis patients. J Enzyme Inhib Med Chem 2017 Dec;32(1):707-711
  Vezzani G et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 70
• 文献情報：
  Garcia Ferrer HR et al. Potential risk factors for reactive arthritis and persistence of symptoms at 2 years: a case-control study with longitudinal follow-up. Clin. Rheumatol. 2018 Feb;37(2):415-422
  Garcia Ferrer HR et al
  2018/01/01
  
• 備考：
  
• 参照：
  

• No.： 71
• 文献情報：
  Lee SM et al. Abdominal aortic calcification score among several vascular calcification scores of plain radiograph is the most reliable predictor of severe coronary artery calcification in dialysis patients. Ren Fail 2017 Nov;39(1):729-735
  Lee SM et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 72
• 文献情報：
  Friedrich MJ et al. RANK-ligand and osteoprotegerin as biomarkers in the differentiation between periprosthetic joint infection and aseptic prosthesis loosening. World J Orthop 2017 Apr;8(4):342-349
  Friedrich MJ et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 73
• 文献情報：
  Bruhn-Olszewska B et al. Prevalence of polymorphisms in OPG, RANKL and RANK as potential markers for Charcot arthropathy development. Sci Rep 2017 03;7(1):501
  Bruhn-Olszewska B et al
  2017/01/01
  
• 備考：
  
• 参照：